Title and Organization:
Ms. Hilleman serves as Chairperson of the Board of Omada Health and a member of the Board of Directors of public life sciences companies Novocure (NVCR), HilleVax ( HLVX), SI-Bone (SIBN) and Minerva Neurosciences (NERV), and of private companies including Omada and the Reiter Affiliated Companies (the international farming arm of Driscoll's Berries). Ms. Hilleman has extensive board committee experience, serving on Audit (Chair), Nominating & Governance, Compensation, Risk, Pricing, and M&A Committees. Previously, Ms. Hilleman served as a public company CFO of diverse global life sciences companies in medical devices, technology and biotechnology companies, including Intersect ENT (acquired), Ocera Therapeutics (acquired), Amyris (AMRS) and Symyx Technologies (acquired). In her role as CFO, she was responsible for raising over one billion dollars in equity and debt financings and led 5 successful initial public offerings and several M&A transactions. Ms. Hilleman graduated from Brown University and earned an MBA from the Wharton School. She is a member of the 1999 class of the Henry Crown Fellows and the Aspen Global Leadership Network at the Aspen Institute and has been recognized by several Silicon Valley award programs for her contributions as a CFO and as a business leader.